GSK News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

GS

Mkt Cap

$99.19B

Volume

6.28M

Next Earnings

October 28th

Loading chart

GS

GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)

GSK

Pay with—

Available Balance0.00

GS

Mkt Cap

$98.21B

Volume

6.28M

Next Earnings

October 28th

Chart Financials Earnings News About Dividends Insider Filings

Could Investing $5,000 in D-Wave Quantum Stock Today Make You a Millionaire?D-Wave Quantum has surged over 1,000% in two years, but the article cautions that much of this rally is driven by hype rather than operational results. While the company shows strong booking growth (1,120% YoY), revenue remains flat at $3.1M and operating losses doubled to $53.3M. With a P/S ratio of 362, the stock is priced for perfection, and analysts suggest waiting for a lower entry point despite the transformational potential of quantum computing technology.The Motley Fool · Oct 15, 2026

Prediction: These 3 Dividend Stocks Will Raise Their Payouts No Matter What the Market DoesThe article identifies three dividend stocks with strong fundamentals and resilient business models that are likely to continue raising payouts through economic downturns: WD-40 Company with 40 years of uninterrupted dividends backed by an iconic product with minimal competition, Energizer Holdings yielding 5.9% with essential consumer products, and Haleon with a conservative payout policy and health brands used by over a billion consumers worldwide.The Motley Fool · Oct 14, 2026

MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?Moderna's stock gained over 5% in a week, adding $4.2 billion in market value, driven by positive phase III melanoma results for its cancer therapy intismeran and inclusion in the Nasdaq-100 Index. While the company shows promise in oncology and respiratory vaccines, its 625% YTD rally has resulted in a premium valuation that leaves it vulnerable to disappointment. The stock is rated a Hold, with short-term investors advised to book profits while long-term investors may consider holding for future growth opportunities.Zacks Investment Research · Oct 13, 2026

Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?The article compares Moderna and Vertex Pharmaceuticals as investment options for 2026. Moderna is expanding its mRNA platform into RSV and oncology but faces profitability challenges with a $2.8B net loss in FY2025 and 39.2% revenue decline. Vertex dominates the cystic fibrosis market with $12.1B revenue, 32.7% net margins, and $3.2B free cash flow, while diversifying into gene therapy and pain management. The author recommends Vertex for its established profitability and growing pipeline, though acknowledges Moderna's long-term platform potential.The Motley Fool · Oct 13, 2026

Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | DelveInsightThe complicated urinary tract infections (cUTI) market is expected to grow steadily through 2036, driven by rising antimicrobial resistance, increasing recurrent and hospital-acquired infections, and recent drug approvals. Key approvals include GSK/Spero Therapeutics' UTEBZI (oral antibiotic) and Wockhardt's ZAYNICH (intravenous antibiotic), both approved in 2026. Emerging therapies from companies like Venatorx Pharmaceuticals, Meiji Seika Pharma, and Locus Biosciences targeting multidrug-resistant Gram-negative bacteria are expected to further expand the market.GlobeNewswire Inc. · Oct 12, 2026

Hatteras Venture Partners Names Sir Andrew Witty as Chairman and Ned Sharpless, M.D., as Managing Director of Hatteras Discovery Innovation, Expanding Proven Investment StrategiesHatteras Venture Partners appointed Sir Andrew Witty as Chairman and Dr. Ned Sharpless as Managing Director of Hatteras Discovery Innovation. The firm announced the first closing of Hatteras Opportunity Fund II targeting $100 million, bringing total capital under management to over $1 billion. The new Discovery strategy aims to replicate the success of the original 2012 initiative that seeded 11 companies and contributed to two FDA-approved medicines.GlobeNewswire Inc. · Sep 30, 2026

GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?GSK and Sanofi, two major European pharmaceutical companies, are compared across growth drivers, pipelines, and valuations. GSK shows strong specialty medicines growth (14% in H1 2026) with expanding oncology and HIV franchises, while Sanofi benefits from blockbuster Dupixent sales (up 28.6%) and stronger near-term earnings growth. Despite both holding Hold ratings, Sanofi appears better positioned due to superior earnings growth outlook, favorable valuation metrics, and positive estimate revisions, though it faces vaccine sales headwinds and heavy Dupixent reliance.Zacks Investment Research · Sep 29, 2026

HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid TumorsHUTCHMED has initiated a Phase Ia global clinical trial of HMPL-A830, a first-in-class antibody-targeted therapy conjugate combining a KRAS inhibitor with an anti-EGFR antibody for treating solid tumors. The first patient was dosed on September 24, 2026. HUTCHMED entered an exclusive development and licensing agreement with GSK on September 3, 2026, granting GSK worldwide rights (excluding Greater China) for development and commercialization.GlobeNewswire Inc. · Sep 28, 2026

Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive LandscapeThe global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.GlobeNewswire Inc. · Sep 17, 2026

Hypertension Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsightOver 100 pharmaceutical companies are actively developing 110+ pipeline hypertension drugs, with approximately 40+ in late-stage development. Key players include Gossamer Bio, Alnylam Therapeutics, Roche, GSK, and others pursuing novel mechanisms like RNA interference and CRAC channel inhibitors. Recent developments include FDA acceptance of lorundrostat's NDA, initiation of zilebesiran's Phase III cardiovascular outcomes trial, and multiple clinical advances in emerging therapies targeting uncontrolled and resistant hypertension.GlobeNewswire Inc. · Sep 16, 2026

to start trading

GS

GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)

GSK

Pay with—

Available Balance0.00

Your PositionYou don't own any GSK yet.

Related Tickers

Earnings

Dividends

Last · Aug 14Quarterly

Amount$0.45

Yield3.67%

Annual$1.82